OTHER INCOME (NET) (Tables)

6 Months Ended

Jun. 30, 2018

Other Nonoperating Income (Expense) [Abstract]

Schedule Of Other Income Expense [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
Dollars in Millions	2018			2017			2018			2017
Interest expense	$	45		$	52		$	91		$	97
Investment income	(38		)	(29		)	(74		)	(55		)
Loss/(gain) on equity investments	356			(5		)	341			(12		)
Provision for restructuring	37			15			57			179
Litigation and other settlements	(1		)	(5		)	(1		)	(489		)
Equity in net income of affiliates	(27		)	(20		)	(51		)	(38		)
Divestiture gains	(25		)	—			(70		)	(127		)
Royalties and licensing income	(353		)	(685		)	(720		)	(884		)
Transition and other service fees	(1		)	(13		)	(5		)	(20		)
Pension and postretirement	(19		)	(11		)	(30		)	(10		)
Intangible asset impairment	—			—			64			—
Loss on debt redemption	—			109			—			109
Other	22			6			(6		)	(15		)
Other income (net)	$	(4	)	$	(586	)	$	(404	)	$	(1,265	)

• Loss/(gain) on equity investments includes a $407 million fair market value adjustment related to the equity investment in Nektar in the second quarter of 2018.

• Litigation and other settlements includes BMS's share of a patent-infringement litigation settlement of $481 million related to Merck's PD-1 antibody Keytruda* in the first quarter of 2017.

• Royalties and licensing income includes upfront licensing fees of $470 million from Biogen and Roche in the second quarter of 2017.